Pharmacokinetics and pharmacodynamics of extended-release glipizide GITS compared with immediate-release glipizide in patients with type II diabetes mellitus

Journal of Clinical Pharmacology

Volumn 42, Issue 6, 2002, Pages 651-657

  Chung, Menger ^a   Kourides, Ione ^a   Canovatchel, William ^a   Sutfin, Tamara ^a   Messig, Michael ^a   Chaiken, Rochelle L ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIPIZIDE; ANTIDIABETIC AGENT; INSULIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELAYED RELEASE FORMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; BLOOD; COMPARATIVE STUDY; MIDDLE AGED;

ADULT; AGED; BLOOD GLUCOSE; COMPARATIVE STUDY; CROSS-OVER STUDIES; DIABETES MELLITUS, NON-INSULIN-DEPENDENT; GLIPIZIDE; HUMAN; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGE; SUPPORT, NON-U.S. GOV'T; DIABETES MELLITUS, TYPE 2; HUMANS; MIDDLE AGED;

EID: 0036000316     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00970002042006007     Document Type: Article

References (21)

1. U.K. prospective diabetes study 16: Overview of 6 years' therapy of type II diabetes: A progressive disease
2. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus
3. Pharmacologic therapy for type 2 diabetes mellitus
4. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide
5. Pharmacokinetics and pharmacodynamics of glipizide after once daily and divided doses
6. The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus
7. Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system: A controlled-release formulation of nifedipine
8. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation
9. Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM
10. Intensive blood-glucose control with sulphonylureas or insulin compared with immediate treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
11. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
12. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
13. Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom Prospective Diabetes Study (UKPDS 47)
14. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49)
15. Patient outcomes after formulary conversion from immediate-release to extended-release glipizide tablets
16. Glipizide-GITS does not increase the hypoglycaemic effect of mild exercise during fasting in NIDDM
17. Effect of glipizide GITS on insulin sensitivity, glycemic indices, and abdominal fat composition in NIDDM
18. Glipizide GITS therapy improved glycemic control without increasing body weight or adversely affecting plasma lipids in a large double-blind, placebo-controlled efficacy and safety trial
19. Long-term glipizide GITS (GXL) therapy does not cause weight gain
20. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus